# EDGAR Filing Document

**Accession Number:** 0001740279
**File Stem:** 0001193125-26-212451
**Filing Date:** 2026-5
**Character Count:** 25582
**Document Hash:** d50dfbd09eac686067411928c559ab8d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-212451.hdr.sgml**: 20260507

**ACCESSION NUMBER**: 0001193125-26-212451

**CONFORMED SUBMISSION TYPE**: S-8 POS

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20260507

**DATE AS OF CHANGE**: 20260507

**EFFECTIVENESS DATE**: 20260507

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IN8BIO, INC.
- **CENTRAL INDEX KEY:** 0001740279
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 825462585
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8 POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-285798
- **FILM NUMBER:** 26954933

**BUSINESS ADDRESS:**
- **STREET 1:** EMPIRE STATE BUILDING
- **STREET 2:** 350 5TH AVENUE, SUITE 5330
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10118
- **BUSINESS PHONE:** (646) 600-6438

**MAIL ADDRESS:**
- **STREET 1:** EMPIRE STATE BUILDING
- **STREET 2:** 350 5TH AVENUE, SUITE 5330
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10118

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Incysus Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20180510

**As filed with the Securities and Exchange Commission on May 7, 2026** 

**Registration No. 333-259458** 

**Registration No. 333-264893** 

**Registration No. 333-274092** 

**Registration No. 333-276614** 

**Registration No. 333-285798** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549**

**POST-EFFECTIVE AMENDMENT NO. 2** 

**(File Nos. 333-259458 and 333-264893)** 

**AND** 

**POST-EFFECTIVE AMENDMENT NO. 1** 

**(File Nos. 333-274092, 333-276614 and 333-285798)** 

**TO** 

**FORM S-8**

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## IN8BIO, INC.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **82-5462585** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |
| **350 5th Avenue, Suite 5330**<br> **New York, New York** | **10118** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**2018 Equity Incentive Plan, as Amended** 

**2020 Equity Incentive Plan** 

**Amended and Restated 2023 Equity Incentive Plan** 

**Amended and Restated 2026 Equity Incentive Plan** 

**(Full titles of the plans)** 

**William Ho** 

**Chief Executive Officer** 

**IN8bio, Inc.** 

**350 5th Avenue, Suite 5330, New York, New York 10118** 

**(Name and address of agent for service)** 

**(646) 600-6438**

**(Telephone number, including area code, of agent for service)** 

***Copies to:***

**Jaime L. Chase** 

**Cooley LLP** 

**1299 Pennsylvania Avenue, NW, Suite 700** 

**Washington, DC 20004** 

**(202) 842-7800** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large Accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

IN8bio, Inc. (the "Registrant") is filing (i) this Post-Effective Amendment No. 2 to each of the Registrant's registration statements on Form S-8 (File Nos. 333-259458 and 333-264893), as filed with the Securities and Exchange Commission (the "SEC") on September 10, 2021 and May 12, 2022, respectively, and each as amended by the Post-Effective Amendment No. 1 to each registration statement filed with the SEC on August 18, 2023, and (ii) this Post-Effective Amendment No. 1 to each of the Registrant's registration statements on Form S-8 (File Nos. 333-274092, 333-276614 and 333-285798), as filed with the SEC on August 18, 2023, January 19, 2024 and March 13, 2025, respectively (collectively, the "Prior Registration Statements"). Pursuant to the Prior Registration Statements, shares of common stock, par value $0.0001 per share, of the Registrant ("Common Stock") were registered for issuance under the Registrant's 2018 Equity Incentive Plan, as amended (the "2018 Plan"), 2020 Equity Incentive Plan (the "2020 Plan"), and Amended and Restated 2023 Equity Incentive Plan (the "2023 Plan" and, together with the 2018 Plan and 2020 Plan, the "Prior Plans").

The Registrant's Board of Directors (the "Board") resolved not to make any further awards under the 2018 Plan following the completion of the Registrant's initial public offering, but the terms of such plan continue to govern all outstanding awards granted thereunder. On November 2, 2020, the Board adopted the 2020 Plan, subject to approval by the Company's stockholders, which became effective with such stockholder approval on November 5, 2020. The 2020 Plan replaced and was the successor to the 2018 Plan. On April 29, 2023, the Board adopted the 2023 Plan, subject to approval by the Company's stockholders, which became effective with such stockholder approval on June 15, 2023. The 2023 Plan replaced and was the successor to the 2020 Plan.

On March 26, 2026, the Board approved the Registrant's Amended and Restated 2026 Equity Incentive Plan (the "2026 Plan"), subject to stockholder approval of the 2026 Plan. On May 7, 2026, the Registrant's stockholders approved the 2026 Plan and the 2026 Plan became effective. The 2026 Plan replaces and is the successor to the 2023 Plan. Upon effectiveness of the 2026 Plan on May 7, 2026 (the "Effective Time"), no new grants could be made under the 2023 Plan but the terms of such plan continue to govern all outstanding awards granted thereunder.

As provided in the 2026 Plan, from and after the Effective Time, all shares of Common Stock that become Prior Plan Returning Shares (as defined below) will be available for grants of new awards under the 2026 Plan. The term "Prior Plan Returning Shares" means shares of Common Stock subject to outstanding stock awards granted under the Prior Plans and that following the Effective Time: (A) are not issued because such stock award or any portion thereof expires or otherwise terminates without all of the shares covered by such stock award having been issued; (B) are not issued because such stock award or any portion thereof is settled in cash; (C) are forfeited back to or repurchased by the Registrant because of the failure to meet a contingency or condition required for the vesting of such shares; (D) are withheld or reacquired to satisfy the exercise, strike or purchase price; or (E) are withheld or reacquired to satisfy a tax withholding obligation.

The Registrant is filing these Post-Effective Amendments pursuant to SEC Corporation Finance Interpretation 126.43 to amend the Prior Registration Statements to register the offer of the Prior Plan Returning Shares under the 2026 Plan (as such shares would no longer be issuable under the 2023 Plan as described above). As of the date of the filing of these Post-Effective Amendments, the maximum number of shares of Common Stock initially registered for offer pursuant to the Prior Plans that may become Prior Plan Returning Shares and available for offer under the 2026 Plan is 646,630 shares. No additional securities are being registered by these Post-Effective Amendments.

**PART I** 

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS** 

**Item 1. Plan Information.** 

Not required to be filed with this Post-Effective Amendment.

**Item 2. Registrant Information and Employee Plan Annual Information.** 

Not required to be filed with this Post-Effective Amendment.

------

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 3. Incorporation of Documents by Reference.** 

The Registrant hereby incorporates by reference into this Registration Statement the following documents filed by it with the Commission:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the contents of the Registrant's Registration Statements on Form S-8, previously filed with the Commission on [September 10, 2021](http://www.sec.gov/Archives/edgar/data/1740279/000119312521270077/d216810ds8.htm) , as amended on [August 18, 2023](http://www.sec.gov/Archives/edgar/data/1740279/000119312523216045/d387080ds8pos.htm) (File No. 
333-259458), [May 12, 2022](http://www.sec.gov/Archives/edgar/data/1740279/000119312522148782/d313321ds8.htm) (333-264893), as amended on [August 18, 2023](http://www.sec.gov/Archives/edgar/data/1740279/000119312523216041/d387080ds8pos.htm) , [August 18, 2023](http://www.sec.gov/Archives/edgar/data/1740279/000119312523216033/d512282ds8.htm) (File No. 
333-274092), [January 19, 2024](http://www.sec.gov/Archives/edgar/data/1740279/000119312524011235/d691824ds8.htm) (333-276614) and [March 13, 2025](http://www.sec.gov/Archives/edgar/data/1740279/000119312525054019/d936078ds8.htm) (File No. 333-285798);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the Registrant's [Annual Report on Form 10-K](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001740279/000119312526104181/inab-20251231.htm) (File No. 001-39692) for the fiscal year ended December 31, 2025, filed with the Commission on March 12, 2026;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the information specifically incorporated by reference into the Registrant's Annual Report on Form 10-K for the fiscal year ended December 
31, 2025 from the Registrant's [Definitive Proxy Statement on Schedule 14A](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001740279/000119312526126208/d26327ddef14a.htm) filed with the Commission on
March 26, 2026;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) the Registrant's [Quarterly Report on Form 10-Q](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1740279/000119312526212135/inab-20260331.htm) (File No. 001-39692) for the three months ended March 31, 2026, filed with the Commission on May 7, 2026;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) the Registrant's Current Reports on Form 8-K (File No. 001-39692), filed with the Commission on [February 9, 2026](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001740279/000119312526041975/d50284d8k.htm) , [February 27, 2026](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001740279/000119312526082539/d915471d8k.htm) and [May 7, 2026](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1740279/000119312526212128/inab-20260507.htm) to the extent the information in and exhibits to such reports are filed and not
furnished; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) the description of the Registrant's common stock contained in [Exhibit 4.2](http://www.sec.gov/Archives/edgar/data/1740279/000119312526104181/inab-ex4_2.htm) to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (File No. 001-39692), filed with the Commission on
March 12, 2026, including any amendments or reports filed for the purpose of updating such description.

All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

**Item 4. Description of Securities.** 

Not applicable.

**Item 5. Interests of Named Experts and Counsel.** 

As of the date hereof, GC&H Investments and GC&H Investments, LLC, each an entity that is comprised of partners and associates of Cooley LLP, beneficially own an aggregate of 5,797 shares of the Registrant's common stock.

**Item 6. Indemnification of Directors and Officers.** 

Section 145 of the Delaware General Corporation Law authorizes a court to award, or a corporation's board of directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act. The Registrant's amended and restated certificate of incorporation provides for indemnification of the Registrant's directors to the maximum extent permitted by the Delaware General Corporation Law, and the Registrant's amended and restated bylaws provide for indemnification of the Registrant's directors, officers, employees and other agents to the maximum extent permitted by law.

------

The Registrant has entered into indemnification agreements with the Registrant's directors and officers, whereby the Registrant has agreed to indemnify the Registrant's directors and officers to the fullest extent permitted by law, including advancement of expenses incurred in legal proceedings to which the director or officer was, or is threatened to be made, a party by reason of the fact that such director or officer is or was a director, officer, employee or agent of the Registrant, provided that such director or officer acted in good faith and in a manner that the director or officer reasonably believed to be in, or not opposed to, the best interest of the Registrant. At present, there is no pending litigation or proceeding involving a director or officer of the Registrant regarding which indemnification is sought, nor is the Registrant aware of any threatened litigation that may result in claims for indemnification.

The Registrant maintains insurance policies that indemnify the Registrant's directors and officers against various liabilities arising under the Securities Act and the Exchange Act that might be incurred by any director or officer in his capacity as such.

**Item 7. Exemption from Registration Claimed.** 

Not applicable.

**Item 8. Exhibits.** 

The exhibits to this Registration Statement are listed below:

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Exhibit Description** |
| 4.1 | [Amended and Restated Certificate of Incorporation of the Company (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K (File No. 001-39692), filed with the SEC on August 3, 2021).](http://www.sec.gov/Archives/edgar/data/1740279/000110465921099436/tm2030088d31_ex3-1.htm) |
| 4.2 | [Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K (File No. 001-39692), filed with the SEC on June 4, 2025).](http://www.sec.gov/Archives/edgar/data/1740279/000119312525134487/d927529dex31.htm) |
| 4.3 | [Second Amended and Restated Bylaws of the Company (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K (File No. 001-39692), filed with the SEC on December 7, 2023).](http://www.sec.gov/Archives/edgar/data/1740279/000119312523290707/d634027dex31.htm) |
| 5.1\* | [Opinion of Cooley LLP.](d113246dex51.htm) |
| 23.1\* | [Consent of Independent Registered Public Accounting Firm.](d113246dex231.htm) |
| 23.2\* | [Consent of Cooley LLP (included in Exhibit 5.1).](d113246dex51.htm) |
| 24.1\* | [Power of Attorney (included on the signature page to this Registration Statement).](#sig) |
| 99.1 | [Amended and Restated 2026 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K (File No. 001-39692), filed with the SEC on May 7, 2026).](http://www.sec.gov/Archives/edgar/data/1740279/000119312526212128/inab-ex10_1.htm) |

---

\* Filed herewith.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York on May 7, 2026.

---

| | |
|:---|:---|
| **IN8bio, Inc.** | **IN8bio, Inc.** |
| By: | /s/ William Ho |
|  | William Ho |
|  | *Chief Executive Officer* |

---

**POWER OF ATTORNEY** 

**KNOW ALL PERSONS BY THESE PRESENTS,** that each person whose signature appears below constitutes and appoints William Ho and Patrick McCall, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ William Ho<br> **William Ho** | Chief Executive Officer and Director<br> (Principal Executive Officer) | May 7, 2026 |
| /s/ Patrick McCall<br> **Patrick McCall** | Chief Financial Officer<br> (Principal Financial Officer and Principal Accounting Officer) | May 7, 2026 |
| /s/ Jeremy R. Graff<br> **Jeremy R. Graff** | Interim Chairman of the Board of Directors | May 7, 2026 |
| /s/ Peter Brandt<br> **Peter Brandt** | Director | May 7, 2026 |
| /s/ Corinne Epperly<br> **Corinne Epperly** | Director | May 7, 2026 |
| /s/ Emily T. Fairbairn<br> **Emily T. Fairbairn** | Director | May 7, 2026 |
| /s/ Luba Greenwood<br> **Luba Greenwood** | Director | May 7, 2026 |

---

## Exhibit 5.1

**Exhibit 5.1**![LOGO](g113246g0507053925206.jpg)

Jaime L. Chase

T: +1 202 728 7096

jchase@cooley.com

May 7, 2026

IN8bio, Inc.

350 5th Avenue

Suite 5330

New York, New York 10118

Ladies and Gentlemen:

We have acted as counsel to IN8bio, Inc., a Delaware corporation (the "***Company***"), in connection with the filing by the Company with the Securities and Exchange Commission (the "***Commission***") of (i) a Post-Effective Amendment No. 2 to each of the Company's registration statements on Form S-8 (File Nos. 333-259458 and 333-264893), as filed with the Commission on September 10, 2021 and May 12, 2022, respectively, and each as amended by the Post-Effective Amendment No. 1 to each registration statement filed with the Commission on August 18, 2023, and (ii) a Post-Effective Amendment No. 1 to each of the Company's registration statements on Form S-8 (File Nos. 333-274092, 333-276614 and 333-285798), as filed with the Commission on August 18, 2023, January 19, 2024 and March 13, 2025, respectively (such registration statements, collectively, the "***Prior Registration Statements***," and the post-effective amendment to each of the Prior Registration Statements, collectively, the "***Post-Effective Amendments***").

The Prior Registration Statements covered the offering of shares of the Company's common stock, par value $0.0001 per share ("***Common Stock***"), previously available for issuance under the Company's 2018 Equity Incentive Plan, as amended (the "***2018 Plan***"), 2020 Equity Incentive Plan (the "***2020 Plan***"), and Amended and Restated 2023 Equity Incentive Plan (the "***2023 Plan***" and, together with the 2018 Plan and 2020 Plan, the "***Prior Plans***"). For purposes of this opinion, the "***Shares***" means up to 646,630 shares of Common Stock, which is the number of shares of Common Stock subject to outstanding stock awards granted under the Prior Plans that, from and after May 7, 2026, may become available for grant under the Company's Amended and Restated 2026 Equity Incentive Plan (the "***2026 Plan***") as described in the Post-Effective Amendments.

In connection with this opinion, we have examined and relied upon (a) the Prior Registration Statements, the Post-Effective Amendments and related prospectuses, (b) the Company's certificate of incorporation and bylaws, each as currently in effect, (c) the Prior Plans, (d) the 2026 Plan, and (e) such records, documents, certificates, memoranda and instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution and delivery of all documents by all persons other than the Company. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

Cooley LLP 1299 Pennsylvania Avenue NW Suite 700 Washington, DC 20004-2400

t: +1 202 842 7800 f: +1 202 842 7899 cooley.com

------

May 7, 2026

Page Two

On the basis of the foregoing, and in reliance thereon and subject to the assumptions, exceptions, limitations and qualifications set forth herein, we are of the opinion that the Shares, when sold and issued in accordance with the 2026 Plan, the Post-Effective Amendments and related prospectuses, will be validly issued, fully paid, and nonassessable (except as to shares issued pursuant to deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

This opinion is limited to the matters expressly set forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or responsibility to update or supplement this letter to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.

We consent to the filing of this opinion as an exhibit to the Post-Effective Amendments. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.

---

| | |
|:---|:---|
| Sincerely, | Sincerely, |
| COOLEY LLP | COOLEY LLP |
| By: | /s/ Jaime L. Chase |
|  | Jaime L. Chase |

---

Cooley LLP 1299 Pennsylvania Avenue NW Suite 700 Washington, DC 20004-2400

t: +1 202 842 7800 f: +1 202 842 7899 cooley.com

## Exhibit 23.1

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in this Post-effective Amendment No. 1 to the Registration Statements on Form S-8 (333-285798, 333-276614, and 333-274092) and Post-effective Amendment No. 2 to the Registration Statements on Form S-8 (333-264893 and 333-259458) of our report dated March 12, 2026, with respect to the financial statements of IN8bio, Inc. as of December 31, 2025 and 2024, and for the years then ended, which report is included in the Annual Report on Form 10-K of IN8bio, Inc. for the year ended December 31, 2025 filed with the Securities and Exchange Commission. Our audit report includes an explanatory paragraph relating to IN8bio, Inc.'s ability to continue as a going concern.

/s/ CohnReznick LLP

New York, New York

May 7, 2026